Drug news
First trial of LEISH - F3 + GLA-SE for Leishmaniasis
The nonprofit Infectious Disease Research Institute has commenced the world's first clinical trial of a vaccine against Leishmaniasis. The vaccine, code-named LEISH�F3 + GLA-SE, includes a recombinant form of two fused Leishmania parasite proteins with an adjuvant to promote the immune response. The first trial, which is taking place in Washington, will include 36 volunteers who will receive the vaccine with three different doses of the adjuvant. This will be followed up with a Phase I trial in healthy volunteers in India with Gennova Biopharmaceuticals, in collaboration with the Banaras Hindu University. The Phase I trials are funded by the Bill & Melinda Gates Foundation
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins